PT4153133T - Composições farmacêuticas injetáveis e utilizações das mesmas - Google Patents

Composições farmacêuticas injetáveis e utilizações das mesmas

Info

Publication number
PT4153133T
PT4153133T PT217278217T PT21727821T PT4153133T PT 4153133 T PT4153133 T PT 4153133T PT 217278217 T PT217278217 T PT 217278217T PT 21727821 T PT21727821 T PT 21727821T PT 4153133 T PT4153133 T PT 4153133T
Authority
PT
Portugal
Prior art keywords
pharmaceutical compositions
injectable pharmaceutical
injectable
compositions
pharmaceutical
Prior art date
Application number
PT217278217T
Other languages
English (en)
Original Assignee
Intervet Int Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Intervet Int Bv filed Critical Intervet Int Bv
Publication of PT4153133T publication Critical patent/PT4153133T/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/10—Anthelmintics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/14—Ectoparasiticides, e.g. scabicides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Dispersion Chemistry (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
PT217278217T 2020-05-20 2021-05-19 Composições farmacêuticas injetáveis e utilizações das mesmas PT4153133T (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP20175597 2020-05-20

Publications (1)

Publication Number Publication Date
PT4153133T true PT4153133T (pt) 2024-01-12

Family

ID=70779586

Family Applications (1)

Application Number Title Priority Date Filing Date
PT217278217T PT4153133T (pt) 2020-05-20 2021-05-19 Composições farmacêuticas injetáveis e utilizações das mesmas

Country Status (16)

Country Link
US (1) US20230310386A1 (pt)
EP (1) EP4153133B1 (pt)
JP (2) JP7447315B2 (pt)
CN (1) CN115666514A (pt)
AU (1) AU2021277491B2 (pt)
BR (1) BR112022022923A2 (pt)
CA (1) CA3182659A1 (pt)
CL (1) CL2022003194A1 (pt)
CO (1) CO2022016630A2 (pt)
DK (1) DK4153133T3 (pt)
ES (1) ES2969653T3 (pt)
FI (1) FI4153133T3 (pt)
IL (1) IL298259A (pt)
MX (1) MX2022014493A (pt)
PT (1) PT4153133T (pt)
WO (1) WO2021233967A1 (pt)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114146020B (zh) * 2022-02-10 2022-04-29 中国远大集团有限责任公司 一种注射美容产品及其制备方法和应用

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4916154A (en) 1986-09-12 1990-04-10 American Cyanamid Company 23-Imino derivatives of LL-F28249 compounds
ES2086022T3 (es) 1991-07-23 1996-06-16 American Cyanamid Co Composiciones estables para administracion parenteral y su uso.
ATE392887T1 (de) 2000-10-10 2008-05-15 Wyeth Corp Stabilisierte arzneizusammensetzungen zur parenteralen vearbreichung
JP4883296B2 (ja) 2004-03-05 2012-02-22 日産化学工業株式会社 イソキサゾリン置換ベンズアミド化合物及び有害生物防除剤
US8362086B2 (en) 2005-08-19 2013-01-29 Merial Limited Long acting injectable formulations
TWI412322B (zh) 2005-12-30 2013-10-21 Du Pont 控制無脊椎害蟲之異唑啉
TWI430995B (zh) 2007-06-26 2014-03-21 Du Pont 萘異唑啉無脊椎有害動物控制劑
PL2957284T3 (pl) 2007-06-27 2018-08-31 E. I. Du Pont De Nemours And Company Sposób zwalczania szkodników zwierzęcych
TWI556741B (zh) 2007-08-17 2016-11-11 英特威特國際股份有限公司 異唑啉組成物及其作為抗寄生蟲藥上的應用
BRPI0705822A2 (pt) * 2007-10-25 2009-06-23 Schering Plough Saude Animal Ltda formulação injetável com ação prolongada e uso de um agente semi-sintético derivado do grupo das avermectinas, em combinação com um polìmero biodegradável
WO2009063910A1 (ja) 2007-11-12 2009-05-22 Nissan Chemical Industries, Ltd. 光学活性イソキサゾリン化合物の触媒的不斉合成方法
TWI411395B (zh) 2007-12-24 2013-10-11 Syngenta Participations Ag 殺蟲化合物
CA2747060A1 (en) 2008-12-18 2010-07-15 Novartis Ag Isoxazolines derivatives and their use as pesticide
JP5608676B2 (ja) 2008-12-19 2014-10-15 ノバルティス アーゲー イソオキサゾリン誘導体及びその殺虫剤としての使用
JP5679102B2 (ja) 2009-08-03 2015-03-04 日産化学工業株式会社 ジヒドロイソキサゾール置換安息香酸化合物の光学活性体とジアステレオマー塩及びその製造方法
TWI487486B (zh) 2009-12-01 2015-06-11 Syngenta Participations Ag 以異唑啉衍生物為主之殺蟲化合物
WO2011124998A1 (en) 2010-04-08 2011-10-13 Pfizer Inc. Substituted 3,5- di phenyl - isoxazoline derivatives as insecticides and acaricides
RS59297B1 (sr) 2012-09-07 2019-10-31 Zoetis Services Llc Paraziticidalne kombinacije spirocikličnog izoksazolina
JP6209272B2 (ja) 2013-09-30 2017-10-04 ゾエティス・サービシーズ・エルエルシー 長時間作用型スピロイソキサゾリン製剤
UY36570A (es) 2015-02-26 2016-10-31 Merial Inc Formulaciones inyectables de acción prolongada que comprenden un agente activo isoxazolina, métodos y usos de las mismas
SG10201912724SA (en) * 2015-04-08 2020-02-27 Boehringer Ingelheim Animal Health Usa Inc Extended release injectable formulations comprising an isoxazoline active agent, methods and uses thereof
UY37137A (es) 2016-02-24 2017-09-29 Merial Inc Compuestos antiparasitarios de isoxazolina, formulaciones inyectables de acción prolongada que los comprenden, métodos y usos de los mismos
WO2019012377A1 (en) 2017-07-10 2019-01-17 Basf Se MIXTURES COMPRISING AN INSECTICIDE AND A NITRIFICATION INHIBITOR SUCH AS 2- (3,4-DIMETHYL-1H-PYRAZOL-1-YL) SUCCINIC ACID (DMPSA) OR 3,4-DIMETHYL PYRAZOLIUM GLYCOLATE (DMPG)
KR102101969B1 (ko) * 2017-09-06 2020-04-22 (주)인벤티지랩 목시덱틴을 포함하는 마이크로 입자 및 이의 제조 방법
PE20201150A1 (es) * 2017-11-07 2020-10-26 Intervet Int Bv Composiciones farmaceuticas inyectables de isoxazolina y usos de las mismas
CN111295375A (zh) 2017-11-07 2020-06-16 英特维特国际股份有限公司 制备大尺寸异噁唑啉粒子的方法

Also Published As

Publication number Publication date
JP2023523476A (ja) 2023-06-05
CO2022016630A2 (es) 2022-11-29
JP2024010068A (ja) 2024-01-23
ES2969653T3 (es) 2024-05-21
AU2021277491B2 (en) 2024-05-16
CL2022003194A1 (es) 2023-02-03
WO2021233967A1 (en) 2021-11-25
MX2022014493A (es) 2022-12-13
IL298259A (en) 2023-01-01
CN115666514A (zh) 2023-01-31
DK4153133T3 (da) 2024-02-05
EP4153133A1 (en) 2023-03-29
AU2021277491A1 (en) 2022-12-01
BR112022022923A2 (pt) 2022-12-20
CA3182659A1 (en) 2021-11-25
FI4153133T3 (fi) 2024-01-30
EP4153133B1 (en) 2023-11-08
JP7447315B2 (ja) 2024-03-11
US20230310386A1 (en) 2023-10-05

Similar Documents

Publication Publication Date Title
IL287628A (en) Injectable pharmaceutical compounds and their uses
GB202019241D0 (en) Pharmaceutical composition
EP4183391A4 (en) PHARMACEUTICAL COMPOSITION AND USE THEREOF
IL311331A (en) Pharmaceutical preparation and its use
ZA202105586B (en) Pharmaceutical delivery compositions and uses thereof
IL304290A (en) composition of drugs
EP4135699A4 (en) PHARMACEUTICAL COMPOSITIONS
FI4153133T3 (fi) Injektoitavia farmaseuttisia koostumuksia ja niiden käyttöjä
EP4180040A4 (en) PHARMACEUTICAL COMPOSITION AND ITS APPLICATION
ZA202104261B (en) Combination pharmaceutical compositions and methods thereof
EP4100020A4 (en) PHARMACEUTICAL ASPACYTARABINE COMPOSITIONS AND USES THEREOF
NL2027551A (en) 1immunogenic polypeptides and pharmaceutical compositions
GB202118095D0 (en) Combination pharmaceutical composition
GB202118008D0 (en) Combination Pharmaceutical composition
GB202105457D0 (en) Combination pharmaceutical composition
IL300090A (en) Pharmaceutical preparations containing VENGLUSTAT
IL307928A (en) Pharmaceutical preparations containing picroside
GB202208464D0 (en) Pharmaceutical composition
GB202109271D0 (en) Pharmaceutical composition
GB202108387D0 (en) Pharmaceutical composition
GB202107518D0 (en) Pharmaceutical composition
GB202105858D0 (en) Pharmaceutical composition
GB202105462D0 (en) Pharmaceutical composition
GB202105047D0 (en) Pharmaceutical composition
GB202105049D0 (en) Pharmaceutical composition